10x Genomics had its Relative Strength (RS) Rating upgraded from 70 to 74 Friday — a welcome improvement, but still short of the 80 or higher score you prefer to see.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 as they begin their biggest climbs. See if 10x Genomics can continue to show renewed price strength and clear that threshold.
10x Genomics is not currently near a potential buy zone. See if the stock goes on to build a base that could spark a new run.
10x Genomics showed 0% EPS growth in its most recent report. Sales rose 13%.
The company holds the No. 32 rank among its peers in the Medical-Products industry group. Insulet, Boston Scientific and Penumbra are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
